SNDL
SNDL Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.44
+1.77%Year over year
Reported trailing growth
- Revenue
- -1.7%
- EBITDA
- +193.6%
- EBIT
- +84.2%
- EPS
- +75.0%
- Free cash flow
- +1.8%
- Operating cash flow
- +5.5%
Forward estimates
Based on analyst estimates
- Revenue
- +0.4%
- EBITDA
- +24.6%
- EPS
- +55.1%
Three-year CAGR
- Revenue
- +9.9%
- EBITDA
- +216.5%
- EBIT
- +95.7%
- Net income
- +83.4%
- EPS
- +84.1%
- Free cash flow
- +32.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026